• Purity

  >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.

• Endotoxin Level

  <0.10 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by its ability to inhibit BMP-4-induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED    ₅₀ for this effect is 0.1-0.4 μg/mL in the presence of 30 ng/mL of Recombinant Human BMP?4 (Catalog # ).

• Source

  Mouse myeloma cell line, NS0-derived

  Human Noggin (Gln28-Cys232) Accession # Q13253	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #

• N-terminal Sequence    
  Analysis

  No results obtained: Gln28 predicted

• Structure / Form

  Disulfide-linked homodimer

• Predicted Molecular Mass

  49.6 kDa (monomer)

• SDS-PAGE

  58-61 kDa, reducing conditions

Background: Noggin

Noggin is a secreted homodimeric glycoprotein that is an antagonist of bone morphogenetic proteins (BMPs) (1, 2). Human Noggin cDNA encodes a 232 amino acid (aa) precursor protein; cleavage of a 19 aa signal peptide generates the 213 aa mature protein which contains an N-terminal acidic region, a central basic heparin?binding segment and a C-terminal cysteine-knot structure (2). Secreted Noggin probably remains close to the cell surface due to its binding of heparin?containing proteoglycans (3). Noggin is very highly conserved among vertebrates, such that mature human Noggin shares 99%, 99%, 98%, 97% and 89% aa sequence identity with mouse, rat, bovine, equine and chicken Noggin, respectively. Noggin binds some BMPs such as BMP-4 with high affinity and others such as BMP-7 with lower affinity, antagonizing BMP bioactivities by blocking epitopes on BMPs that are needed for binding to both type I and type II receptors (2, 4). During embryogenesis, Noggin antagonizes specific BMPs at defined times during neural tube, somite and cardiomyocyte growth and patterning (5-7). During skeletal development, Noggin prevents chondrocyte hyperplasia, thus allowing proper formation of joints (4). Mutations within the cysteine-knot region of human Noggin are linked to multiple types of skeletal dysplasias that result in apical joint fusions (8). Noggin is expressed in defined areas of the adult central nervous system and peripheral tissues such as lung, skeletal muscle and skin (1). During culture of human embryonic stem cells (hESC) without feeder layers or conditioned medium, but with addition of FGF basic, addition of Noggin to antagonize BMP activity allows hESC to maintain their undifferentiated, pluripotent state (9, 10).

• References:

1. Valenzuela, D.M. et al. (1995) J. Neurosci. 15:6077.

2. Groppe, J. et al. (2002) Nature 420:636.

3. Paine-Saunders, S et al. (2002) J. Biol. Chem. 277:2089.

4. Brunet, L. J. et al. (1998) Science 280:1455.

5. McMahon, J. A. et al. (1998) Genes Dev. 12:1438.

6. Itsykson, P. et al. (2005) Mol. Cell. Neurosci. 30:24.

7. Yuasa, S. et al. (2005) Nat. Biotechnol. 23:607.

8. Gong, Y. et al. (1999) Nat. Genet. 21:302.

9. Xu, R.-H. et al. (2005) Nat. Methods 2:185.

10. Wang, G. et al. (2005) Biochem. Biophys. Res. Commun. 330:934.

• Entrez Gene IDs:

  9241 (Human); 18121 (Mouse)

• Alternate Names:

  NOG; Noggin; SYM1; symphalangism 1 (proximal); synostoses (multiple) syndrome 1; SYNS1